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Abstract
Background: Absolute risk estimation is a preferred approach for assessing fracture risk and treatment decision making. This
study aimed to evaluate and validate the predictive performance of the Garvan Fracture Risk Calculator in a Norwegian
cohort.
Methods: The analysis included 1637 women and 1355 aged 60+ years from the Tromsø study. All incident fragility fractures
between 2001 and 2009 were registered. The predicted probabilities of non-vertebral osteoporotic and hip fractures were
determined using models with and without BMD. The discrimination and calibration of the models were assessed.
Reclassification analysis was used to compare the models performance.
Results: The incidence of osteoporotic and hip fracture was 31.5 and 8.6 per 1000 population in women, respectively; in
men the corresponding incidence was 12.2 and 5.1. The predicted 5-year and 10-year probability of fractures was
consistently higher in the fracture group than the non-fracture group for all models. The 10-year predicted probabilities of
hip fracture in those with fracture was 2.8 (women) to 3.1 times (men) higher than those without fracture. There was a close
agreement between predicted and observed risk in both sexes and up to the fifth quintile. Among those in the highest
quintile of risk, the models over-estimated the risk of fracture. Models with BMD performed better than models with body
weight in correct classification of risk in individuals with and without fracture. The overall net decrease in reclassification of
the model with weight compared to the model with BMD was 10.6% (p = 0.008) in women and 17.2% (p = 0.001) in men for
osteoporotic fractures, and 13.3% (p = 0.07) in women and 17.5% (p = 0.09) in men for hip fracture.
Conclusions: The Garvan Fracture Risk Calculator is valid and clinically useful in identifying individuals at high risk of
fracture. The models with BMD performed better than those with body weight in fracture risk prediction.
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Absolute risk or individualized prognosis is considered to be a
preferred approach in the assessment of fracture risk and
treatment decision making. Several prediction models and tools
have been developed to calculate absolute fracture risk. These
tools vary according to the number and type of fracture risk factors
included, and on the complexity of fracture risk computation [4,5].
Systematic reviews highlighted that simple tools performed as well
as complex tools [5–7]. The Garvan Fracture Risk Calculator
(www.fractureriskcalculator.com) was stated as one of the simplest
tools for fracture prediction developed in a population-based
setting applying proper methodology [5]. It is based on data from

Introduction
Osteoporotic fractures are an important public health problem.
With increasing aging populations, their number will increase
placing an additional burden on individuals and society in terms of
functional limitations, morbidity, mortality, and costs [1–3].
Individuals with high fracture risk are those who can effectively
benefit from preventive measures and pharmaceutical interventions and therefore need to be identified in clinical settings. The
tools used to identify persons with increased fracture risk have
been expanded to rely not only on bone mineral density (BMD)
measurements but also to include informative clinical risk factors.
PLOS ONE | www.plosone.org
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the manufacturer provided protocol. The short term in vivo
precision error was 1.7% and 1.2% for femoral neck and total hip
measurement, respectively, and daily phantom measurements
were stable throughout the survey. All scans were reviewed and
reanalysed if necessary [18]. Technically incorrect scans and scans
of hips with severe deformities were excluded. Scans of the left hip
were used for analyses but, if the left hip measurement was
ineligible, the right hip scan was used.

the Dubbo Osteoporosis Epidemiology Study (DOES) and
integrates sex, age, BMD (or body weight), and history of prior
fracture and falls into the nomograms. It includes two nomograms;
one for prediction of absolute risk for hip fracture and another for
any fragility fracture [8,9]. These nomograms predict the
individualized 5-year or 10-year absolute fracture risk for both
women and men.
Assessment of the performance of prognostic models in different
populations is necessary [4,10,11]. The Garvan Fracture Risk
Calculator was examined in independent cohorts [11–15] and
performed well in predicting fracture. However, these validation
studies compared the nomograms with other prediction tools, and
did not compare the predictive performance between the model
with BMD and the model with body weight.
Norway has the highest incidence of hip fractures in the world
[16]. Therefore, identification of those at high risk of fracture is
warranted, and tools that can be used readily in clinical settings are
definitely needed. The present study was designed to evaluate and
validate the performance of the Garvan nomograms for predicting
5-year and 10-year risk of fragility fracture in an independent
Norwegian cohort of women and men.

Fracture registration
The fracture registry covered the 15-year period from the date
of examination in Tromsø 4 (1994/95) through December 31st
2009 with respect to all non-vertebral fractures. Vertebral
fractures were excluded, as date of occurrence for vertebral
fractures are not reliable. The fracture registry is based on the
radiological archives at the University Hospital of North Norway
in Tromsø. The nearest alternative radiology service or fracture
treatment facility is located 250 km from Tromsø. The only
fractures that would be missed are those, for which no radiology
was performed or where such investigations occurred while the
subject was travelling and without any subsequent local follow-up
examination. The computerized records in the radiological
archives of the University Hospital contain the national personal
identification number (unique for each resident of Norway), time
of investigation, fracture codes and descriptions. All abnormal
radiological examinations were reviewed to ascertain the fracture
code, to identify exact fracture type and anatomical location, to
distinguish consecutive fracture occasions in the same person, and
to capture fractures that had not been coded correctly as fractures.
In addition, the hospital discharge records were checked with
respect to hip fractures. A similar registration has previously been
described and validated [19].

Methods
Study population
The Tromsø Study [17] is a longitudinal population-based
multipurpose study focusing on lifestyle-related diseases. The first
survey was conducted in 1974, with repeated surveys in 1979/80,
1986/87, 1994/95, 2001/02 and 2007/08. The fifth survey in
2001/02 (Tromsø 5) invited all persons living in Tromsø between
55–74 years of age and a randomly selected (5–10%) sub-set of
women and men in the age groups 25–54 and 75–84 years, who
had participated in the second visit of the fourth survey (Tromsø 4)
in 1994/95. Of 10,353 persons invited to the first visit of Tromsø
5, 8,130 (79%) attended, and among them, a preselected random
sample of 6,969 persons were invited for a second visit one month
later, and 5,939 (85%) attended. At the second visit, hip BMD was
measured in 3,094 women and 2,132 men, all of whom had one or
both hips without nails or prostheses.
Women (n = 2256) and men (n = 1702) aged 60 years or older
were selected in order to examine the nomograms performance in
a population of similar age as the population in which the
nomograms were developed. Of these, 1637 women and
1355 men (aged 60+ years) were included in this analysis. Subjects
with missing data were excluded; 603 subjects with missing history
of fall and/or previous fracture, 98 subjects with invalid BMD
measurements, 8 subjects with pathological fractures, 85 subjects
using bisphosphonates, and 184 women using hormone therapy
(numbers are overlapping).
The Regional Committee of Medical Research Ethics and the
Norwegian Data Inspectorate approved the study. All participants
gave written informed consent.

Statistical analysis
Fractures were classified as hip or non-vertebral osteoporotic
fractures. The latter included all non-vertebral fractures except
fractures of the finger, toe, or skull. Descriptive statistics of the
study cohort are presented by sex and fracture status. Comparison
of women and men with and without fracture were performed
using T-test for continuous variables and chi-square test for
categorical variables. Follow-up time was assigned from the date of
the BMD measurement at Tromsø 5 (in 2001/02) for each
participant, to date of first fracture, migration, death, or to
December 31st 2009. Incidence rates (per 1000 person-years) were
calculated by dividing the total number of first incident fractures
by the sum of person-years during the follow-up period.
The Garvan Fracture Risk Calculator (Appendix S1) estimates
the 5-year and 10-year risks of fracture for an individual based on
the individual’s risk profile which includes gender, age, bone
mineral density (or body weight), frequency of falls during the past
12 months, and the frequency of prior fractures [8,9]. Two models
were used; the first model included BMD, age, prior fracture and
fall; the second model replaced BMD with body weight. The
prognostic discrimination - between those who suffered a fracture
and those who did not - of the models was assessed by the area
under the receiver operating characteristics curve (AUC). The
predictive accuracy (calibration) of the two models was assessed by
the concordance index [20], where the concordance between
quintiles of observed and predicted risk of fracture was used as a
measure of fit. Moreover, ratios of the predicted fracture risk
between those with and without fracture were calculated as back
transformation of the log values of the predicted risk difference.
Reclassification analysis [21] was used to compare the prognostic
performance between the two models. In this analysis, the net

Questionnaires and measurements
Two self-administered questionnaires were completed by the
participants, one before entering the survey, and the other
between the two visits of the survey. The questionnaires covered,
among others, history of previous fractures, history of falls in the
last 12 months, and use of medications. Height and weight were
measured to the nearest centimetre/half kilogram whilst wearing
light clothing and no shoes.
Dual hip BMD expressed as g/cm2 was measured by DXA (GE
Lunar Prodigy, LUNAR Corporation, Madison, WI, USA). The
scans were performed by specially trained technicians according to
PLOS ONE | www.plosone.org
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Table 1. Baseline characteristics of women and men. The Tromsø Study.

Non-vertebral osteoporotic fractures

Non-fracture
Variables

Any

p-value*

Hip

p-value*

Women

(n = 1281)

(n = 356)

Age (y)

69.0 (6.3)

70.3 (6.3)

0.001

74.1 (6.3)

,0.001

Height (cm)

160.3 (6.0)

160.9 (5.9)

0.09

160.6 (6.1)

0.74

Weight (kg)

69.5 (11.9)

67.9 (11.3)

0.03

66.1 (11.9)

0.01

Femoral neck BMD (g/cm2)

0.83 (0.12)

0.79 (0.11)

,0.001

0.75 (0.11)

,0.001

Femoral neck T-scores

–1.46 (1.19)

–1.89 (1.10)

,0.001

–2.30 (1.06)

Prior fracture, n (%)

(n = 88)

0.004

0

972 (75.9)

242 (68.0)

60 (68.2)

1

185 (14.4)

68 (19.1)

16 (18.2)

2

89 (7.0)

26 (7.3)

6 (6.8)

3

35 (2.7)

20 (5.6)

Fall in the last 12 month, n (%)

,0.001
0.11

6 (6.8)
0.03

228 (64.0)

0.02

0

903 (70.5)

52 (59.1)

1

360 (28.1)

125 (35.1)

36 (40.9)

2

18 (1.4)

3 (0.8)

0 (0)

Men

(n = 1238)

(n = 117)

Age (y)

69.6 (5.6)

71.1 (6.5)

0.006

72.8 (5.9)

,0.001

Height (cm)

174.2 (6.6)

176.1 (6.4)

0.002

176.7 (6.8)

0.008

80.5 (11.5)

83.0 (13.8)

0.02

82.4 (14.6)

0.26
,0.001

Weight (kg)
2

(n = 47)

Femoral neck BMD (g/cm )

0.94 (0.13)

0.88 (0.13)

,0.001

0.84 (0.1)

Femoral neck T-scores

–0.91 (1.22)

–1.40 (1.18)

,0.001

–1.74 (0.88)

Prior fracture, n (%)

0.057

0

1119 (90.4)

101 (86.3)

38 (80.9)

1

90 (7.3)

10 (8.6)

7 (14.9)

2

21 (1.7)

6 (5.1)

2 (4.2)

3

8 (0.7)

0 (0)

Fall in the last 12 month, n (%)

,0.001
0.12

0 (0)
0.16

0.63

0

856 (69.1)

71 (60.7)

32 (68.1)

1

361 (29.2)

44 (37.6)

15 (31.9)

2

21 (1.7)

2 (1.7)

0 (0)

Values are mean (SD), unless otherwise specified.
* Compared with non-fracture group.
doi:10.1371/journal.pone.0107695.t001

Among 1355 men, 117 suffered non-vertebral osteoporotic
fractures where 47 of them were hip fractures (mean follow-up
7.1 years). During the first 5 years of follow-up, 210 women
suffered non-vertebral fractures (42 hip) and 68 men suffered nonvertebral fractures (24 hip). The incidences per 1000 person-years
of non-vertebral osteoporotic and hip fractures during the followup were, respectively, 31.5 (95% Confidence Interval (CI) 28.3–
34.9) and 8.6 (95% CI 7.0–10.6) in women, and 12.2 (95% CI
10.2–14.6) and 5.1 (95% CI 3.8–6.7) in men. The baseline
characteristics of the study cohort are shown in Table 1.
The area under receiver operating characteristics curve (AUC)
illustrates the prognostic discrimination for non-vertebral osteoporotic and hip fractures of both models (Figure 1A and 1B). The
AUCs for both models were higher for hip (ranging from 0.73 to
0.79) than non-vertebral osteoporotic fractures (AUC 0.61–0.67)
with the highest AUC in the 5-year risk analyses. Moreover, the
AUCs for the model with BMD were significantly higher than the

reclassification improvement (NRI) for fracture prediction was
calculated as the sum of differences in proportions of subjects with
fracture and proportions of subjects without fracture who were
correctly reclassified with higher/lower risk, between the model
with BMD and the model with weight, where positive values would
indicate better performance of the model with weight or vice versa.
The quartiles of the predicted risk from both models were used as
thresholds for the risk groups in the reclassification analysis.
The analyses were performed using the SAS statistical package,
v9.2 (SAS Institute Inc., Cary, NC, USA), STATA 12.0
(StataCorp. 2011. Stata Statistical Software: Release 12. College
Station, TX: StataCorp LP), and R (R core team 2012). The
criterion for statistical significance was set at p,0.05.

Results
Among 1637 women, 356 suffered non-vertebral osteoporotic
fractures including 88 hip fractures (mean follow-up 6.9 years).

PLOS ONE | www.plosone.org
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Figure 1. Receiver Operating Characteristic (ROC) curves for model with BMD (continuous line) and model with weight (dashed
line) for non-vertebral osteoporotic fracture (upper panel) and hip fracture (lower panel) in women and men based on (1A): 5-year
predicted risk, and (1B): 10-year predicted risk.
doi:10.1371/journal.pone.0107695.g001

model with weight for both fracture types among both women and
men (all p,0.05).
With respect to predictive accuracy of the two models
(Figure 2A and 2B), there was a close agreement between
predicted and observed risk of fracture, with higher concordance

PLOS ONE | www.plosone.org

between predicted and observed risk in general for women than
for men. In women and men with fracture risk in the highest
quintile, both BMD and weight models over-estimated the 5-year
and 10-year risks of fracture. Moreover, both the 5-year and the
10-year probability of fracture in those with fracture were on
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Figure 2. Concordance between the predicted and observed risk of non-vertebral osteoporotic fracture (upper panel) and hip
fracture (lower panel) in the Tromsø Study cohort, according to the Garvan nomograms. (A): Quintile cut-offs for the predicted 10-year
risk (%) of non-vertebral osteoporotic fracture in women were: 10.8, 15.3, 21.2 and 31.9 for model with BMD (M1); and 12.5, 16.3, 21.3 and 31.5 for

PLOS ONE | www.plosone.org
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model with weight (M2). Corresponding cut-offs in men were 5.3, 8.0, 11.7 and 18.3 for M1; and 5.9, 8.3, 12.1, 17.9 for M2. Quartile cut-offs for the
predicted 10-year risk (%) of hip fracture in women were: 1.3, 2.6, 4.9 and 11.2 for M1 and 1.7, 2.9, 5.0 and 11.1 for M2; In men, 0.3, 0.8, 1.6 and 3.9 for
M1; and 0.9, 1.5, 2.6 and 4.8 for M2. (B): Quintile cut-offs for the predicted 5-year risk (%) of non-vertebral osteoporotic fracture in women were: 5.2,
7.4, 10.5 and 16.4 for model with BMD (M1); and 6.2, 8.1, 10.8 and 16.5 for model with weight (M2). Corresponding cut-offs in men were 2.8, 4.2, 6.3
and 10.0 for M1; and 3.2, 4.5, 6.6, 10.1 for M2. Quartile cut-offs for the predicted 5-year risk (%) of hip fracture in women were: 0.7, 1.4, 2.7 and 5.8 for
M1 and 0.9, 1.6, 2.8 and 6.3 for M2; In men, 0.2, 0.4, 0.8 and 2.1 for M1; and 0.5, 0.8, 1.4 and 2.7 for M2.
doi:10.1371/journal.pone.0107695.g002

can help make decision concerning treatment for a patient. A
number of fracture risk assessment tools have been developed, and
among the most popular algorithms are the World Health
Organization’s FRAX and Garvan Fracture Risk Calculator.
These algorithms have been widely validated in independent
populations. A recent review of 13 tools for prediction of fractures
found that the Garvan model performed as good as or better than
more complex models [5]. Compared to other tools, the Garvan
nomogram is easy to use without complex computation or the
need of computer software which can be impractical or
inaccessible in primary care settings [9]. Although the nomograms
incorporate fewer number of risk factors compared to other
prediction tools, their good predictive performance might be
attributed to the strong contribution of the cumulative effect of
history of previous fracture and falls on fracture risk [12].
Our findings of moderate discriminative performance of the
nomograms with BMD are similar to those reported earlier on the
10-year prediction model. In New Zealand postmenopausal
women followed more than 8 years, the Garvan nomograms
had AUC values of 0.64 for osteoporotic fractures and 0.67 for
hip fractures [14]. In the Global Longitudinal Study of Osteoporosis in Women (GLOW) study (including 60+ years old women
from 10 countries with 2 years follow-up), the AUC was 0.64 for
osteoporotic fractures and 0.61 for hip fractures [15]. In a
Canadian cohort of women and men followed more than 8 years,
the discrimination was assessed using the Harrell’s C statistics
(analogous to AUC) and found to be 0.69 in women and 0.70 in
men for low-trauma fractures, and 0.80 in women and 0.85 in
men for hip fractures [13]. In addition to previous validations, the
current validation also tested the performance of a model with
body weight instead of BMD. Overall, the discrimination values
for the model with weight were lower than the model with BMD
for both fracture types in women and in men. Nonetheless, the
model with weight showed a modest performance for hip fractures.
The discriminative value (AUC) of a model does not reflect its
clinical value, however evaluation of calibration of prediction
models is important for the translation to clinical practice [22].

average consistently higher than in those without fracture for both
models. The 10-year probability analyses showed that in women,
the ratios of predicted risk of non-vertebral osteoporotic fracture
between fracture and non-fracture groups were 1.30 (95% CI
1.20–1.40) and 1.16 (1.09–1.24) for BMD and weight models,
respectively. The corresponding ratios for hip fracture were,
respectively, 2.80 (2.12–3.70) and 2.02 (1.58–2.59). Similar results
were obtained in men; for non-vertebral osteoporotic fracture 1.36
(1.19–1. 56) and 1.19 (1.05–1.34) for BMD and weight models,
respectively and for hip fracture 3.10 (2.08–4.62) and 1.67 (1.17–
2.28).
Models with BMD performed better than models with weight in
terms of correct reclassification of fracture and non-fracture
subjects in their risk groups in women and in men (Table 2).
Compared to the model with BMD, the model with weight
showed a net decrease of 9.6% in women and 17.1% in men, in
reclassifying non-vertebral osteoporotic fracture cases as ‘‘high
risk’’ group, and a decrease of 1.1% in women and 0.1% in men in
reclassifying non-fracture subjects as ‘‘low risk’’ group. The overall
net decrease in reclassification of the model with weight was
10.6% (p = 0.008) in women and 17.2% (p = 0.001) in men. For
hip fracture, there was no significant difference between the two
models. The overall reclassification index showed a net decrease of
13.3% (p = 0.07) in women and 17.5% (p = 0.09) in men for the
model with weight compared to the model with BMD.

Discussion
This study validated the Garvan nomograms in a new
population with a substantially higher fracture risk. The nomograms were valid and reasonably accurate in identifying individuals at high risk of fracture in this population. The models with
BMD performed better than those with body weight in fracture
prediction.
The assessment of fracture risk is moving toward the absolute
risk approach, in which an individual’s risk is estimated based on
the individual’s unique risk profile. The individualization of risk

Table 2. Net Reclassification Improvement (NRI) of model with body weight compared to model with BMD.

Women

Men

Index

(SE)

p-value

Index

(SE)

p-value

NRI for fracture

–0.096

0.036

0.008

–0.171

0.049

0.0009

NRI for non-fracture

–0.011

0.018

0.536

–0.001

0.017

0.961

NRI overall

–0.106

0.040

0.008

–0.172

0.052

0.001

–0.125

0.070

0.078

–0.191

0.098

0.061

Osteoporotic fracture

Hip fracture
NRI for fracture
NRI for non-fracture

–0.008

0.019

0.676

0.016

0.021

0.450

NRI overall

–0.133

0.072

0.070

–0.175

0.100

0.093

Values are differences in proportion of correct classification between the models with weight and BMD in each category. Negative values showed that the model with BMD
performed better than the model with weight and vice versa.
doi:10.1371/journal.pone.0107695.t002
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Similar to previous validations [13,14], this study showed very
good calibration of the nomograms, particularly in women in the
four lower quintiles of risk. Although the nomograms (with BMD
or body weight) over-estimated the risk of fracture in high risk
individuals, these individuals would be candidates for intervention
in any case. In fact their outcomes may have been modified by
treatment received. However, data on treatment were not
available in the present study. Compared to women and men in
the lower risk quintiles, those in the highest risk quintile were older
and had shorter mean follow-up, indicating an increased
competing risk of death and thus potentially lower observed risk.
In addition, the predicted 10-year risk was compared with an
observed risk of shorter duration (mean follow-up 6.9–7.1 years),
although similar effects were observed in the 5-year risk analyses.
However, possibility of starting osteoporosis treatment during
follow-up or model shrinkage – models’ tendency to overestimate
when using independent data– could contribute to the overestimates [10,13]. Nonetheless, the nomograms overall predictive
ability at the individual level can potentially be useful in clinical
practice and as a measure of severity of osteoporosis for the
identification of patients in need to be on anti-osteoporosis
treatment, and even can be used for selecting patients for clinical
trials [9].
This study provides the first external evaluation of performance
of the model with body weight compared to model with BMD.
The model with BMD performed better in reclassifying both those
with and without fracture. The decrease in reclassification for the
model with weight is attributed to the overall better sensitivity and
specificity of the model with BMD. The reclassification analysis is
useful for comparison of the two models in the same group of
patients, but not for necessarily for assessment of the models’
clinical utility [23]. However, the high predictive accuracy of the
model with weight demonstrated by the calibration performance
indicates its validity in clinical settings where BMD measurements
may not be readily available.
Strengths of this validation analysis include the prospective
population-based design with a long follow-up of a large cohort of
women and men, with a validated fracture registry capturing all
non-vertebral fractures in the cohort. This gave the opportunity to

examine the nomograms performance in a similar study design as
the one in which the nomograms were developed but in a distinct
independent cohort in a distinct geographic location. Limitations
of the study included the lack of vertebral fracture registration, the
identification of the energy involved (i.e. low versus higher trauma)
in all of the fractures, and data on treatment during follow-up,
which would have strengthened the validation. Furthermore, the
results cannot be extrapolated to younger women and men, and
because of lack of certain data, it was not possible to make
performance comparisons between the nomograms and the widely
used FRAX tool [4,5].
In conclusion, the Garvan nomograms were valid and clinically
accurate in discriminating between fracture and non-fracture
subjects in an independent Norwegian cohort of women and men
supporting the robustness of the algorithms. Models with BMD
performed better than those with body weight in fracture
prognosis. Although the nomograms somewhat over-estimated
the risk of fracture in high risk individuals, their predictive ability
would be useful in clinical practice.
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